Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen — Results from a prospective, single center, case control study
2015 ◽
Vol 26
(1)
◽
pp. 63-67
◽
Keyword(s):
Factor V
◽